Key Events This Week
21 Sep: Stock opens strong at Rs.1,161.50 (+0.74%)
22 Sep: Mojo Grade upgraded to Buy by MarketsMOJO
23 Sep: Technical momentum shifts to bullish; price rises to Rs.1,169.50 (+0.73%)
24 Sep: Increased delivery volumes and heavy put options activity
25 Sep: New 52-week high at Rs.1,206.80; sharp open interest surge
21 September: Positive Start Amid Broad Market Gains
Zydus Lifesciences began the week on a positive note, closing at Rs.1,161.50, up 0.74% from the previous Friday’s close. This gain outpaced the Sensex’s 0.46% rise to 35,787.64, signalling early strength in the stock. The volume was moderate at 20,108 shares, reflecting steady investor interest. The stock’s resilience above Rs.1,160 set the tone for the week’s bullish momentum.
22 September: Upgrade to Buy Rating Boosts Confidence
On 22 September, MarketsMOJO upgraded Zydus Lifesciences from a Hold to a Buy rating, citing strong technical and fundamental grounds. This upgrade was driven by improved technical indicators including bullish daily moving averages and positive volume trends, alongside solid long-term fundamentals despite recent quarterly profit pressures. The stock price remained stable at Rs.1,161.00 (-0.04%), but the upgrade laid the foundation for renewed investor optimism.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
23 September: Technical Momentum Shifts to Bullish
The stock gained 0.73% to close at Rs.1,169.50, outperforming the Sensex’s 0.56% rise. This day marked a significant technical shift as the stock’s momentum upgraded from mildly bullish to bullish. Key indicators such as daily moving averages turned firmly positive, while monthly MACD and On-Balance Volume (OBV) supported a strengthening medium-term trend. Despite some weekly oscillators remaining cautious, the overall technical landscape favoured further upside potential.
24 September: Increased Delivery Volumes and Put Options Activity
On 24 September, Zydus Lifesciences closed at Rs.1,180.00, a 0.90% gain despite the Sensex falling 1.62%. Delivery volumes surged by 41.56% to 11.02 lakh shares, indicating strong investor conviction beyond speculative trading. The derivatives market saw heavy put options activity, signalling hedging or cautious positioning amid the stock’s recent rally. This day’s price action and volume dynamics underscored robust demand and consolidation near recent highs.
25 September: New 52-Week High and Sharp Open Interest Surge
The stock reached a new 52-week high of Rs.1,206.80 intraday, closing at Rs.1,202.00 with a 1.86% gain, significantly outperforming the Sensex’s 0.18% rise. This marked the culmination of a strong week-long rally. Open interest in derivatives surged 18.43% to 27,717 contracts, accompanied by a futures turnover of approximately ₹88,799 lakhs and options turnover of ₹4,354 crore. The alignment of all key moving averages above the current price and bullish volume indicators reinforced the positive technical outlook.
Want to dive deeper on Zydus Lifesciences Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Daily Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-21 | Rs.1,161.50 | +0.74% | 35,787.64 | +0.46% |
| 2026-09-22 | Rs.1,161.00 | -0.04% | 35,672.04 | -0.32% |
| 2026-09-23 | Rs.1,169.50 | +0.73% | 35,870.78 | +0.56% |
| 2026-09-24 | Rs.1,180.00 | +0.90% | 35,291.38 | -1.62% |
| 2026-09-25 | Rs.1,202.00 | +1.86% | 35,353.29 | +0.18% |
Key Takeaways
Strong Outperformance: Zydus Lifesciences outpaced the Sensex by over 5% during the week, reflecting robust investor demand and positive sentiment.
Technical Upgrade: The shift from mildly bullish to bullish technical momentum, supported by moving averages, MACD, and OBV, underpinned the stock’s gains.
Rating Upgrade: The MarketsMOJO upgrade to a Buy rating on 22 September reinforced confidence in the stock’s medium-term prospects despite recent quarterly profit declines.
Derivatives Market Activity: A sharp 18.43% rise in open interest and elevated futures and options turnover signalled strong bullish positioning and increased liquidity.
Valuation and Fundamentals: The stock’s new 52-week high at Rs.1,206.80 was supported by attractive valuation metrics including a ROCE of 21.8% and a low debt-to-equity ratio of 0.05 times, despite short-term profitability pressures.
Volume and Delivery Trends: Rising delivery volumes indicated genuine accumulation by investors, reducing concerns of speculative trading.
Conclusion
Zydus Lifesciences Ltd demonstrated a compelling combination of technical strength, fundamental resilience, and market interest during the week ending 25 September 2026. The stock’s 4.25% weekly gain, achieved amid a declining Sensex, highlights its relative strength within the mid-cap pharmaceutical sector. The upgrade to a Buy rating by MarketsMOJO, coupled with a new 52-week high and a surge in derivatives open interest, points to growing investor confidence and a positive risk-reward profile. While recent quarterly results showed some profit pressures, the company’s conservative capital structure, consistent sales growth, and strong returns on equity and capital employed provide a solid foundation for sustained performance. Investors should monitor the stock’s ability to maintain momentum above the 52-week high and watch for any shifts in broader market conditions that could influence its trajectory.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
